Hailing Hsu

This inventor holds 27 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 9 EPO patents, primarily in Biopharmaceutical Proteins. Top assignees: Amgen Inc., Tularik Limited. Active years: 1996-2026.

USPTO Granted Patents = 27 (Patent Applications = 4)

% Patents Active = 66.7

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 125(Granted Patents)

Location History:

South San Francisco, CA (US) (1996)
Moon Park, CA (US) (2001 - 2006)
Moorpark, CA (US) (2003 - 2022)

Company Filing History:

Years Active: 1996-2026

Loading Chart...

Areas of Expertise:

Biopharmaceuticals

Anti-TL1A Antibodies

BAFF Proteins

TNF Receptor

Heterodimer Antibodies

Signal Transduction

Peptides

Alpha-4-Beta-7 Antagonist

TALL-1 Binding

Nucleic Acids

Fusion Proteins

TNF Ligand Family

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630598 - IL-10 muteins and fusion proteins thereof (2026-05-19),

2. 12552877 - Anti-TL1A antibodies and uses thereof (2026-02-17),

3. 12479930 - PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF (2025-11-25),

4. 11492417 - Proteins specific for BAFF and B7RP1 and uses thereof (2022-11-08),

5. 11104745 - Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof (2021-08-31),

6. 10421824 - Proteins specific for BAFF and B7RP1 (2019-09-24),

7. 10421823 - Proteins specific for BAFF and B7RP1 and uses thereof (2019-09-24),

8. 9914779 - Administration of alpha4beta7 hetero-dimer-specific antibody (2018-03-13),

9. 9499620 - Methods of using an alpha-4-beta-7 heterodimer specific antagonist antibody (2016-11-22),

10. 9458246 - Proteins specific for BAFF and B7RP1 (2016-10-04),

11. 9139645 - Peptides and related molecules that bind to TALL-1 (2015-09-22),

12. 8871490 - Alpha-4-beta-7 heterodimer specific antagonist antibody (2014-10-28),

13. 8507426 - Peptides and related molecules that bind to TALL-1 (2013-08-13),

14. 8454962 - Alpha-4-beta-7 heterodimer specific antagonist antibody (2013-06-04),

15. 8454961 - Alpha-4-beta-7 heterodimer specific antagonist antibody (2013-06-04),

Title: Hailing Hsu: A Pioneer in Bispecific Protein Innovations

Introduction

Hailing Hsu, based in Moorpark, CA, has established himself as a prominent inventor in the field of biopharmaceuticals. With an impressive portfolio of 24 patents, his work focuses primarily on innovative bispecific proteins aimed at targeting specific diseases. His contributions significantly advance the understanding and treatment of complex medical conditions.

Latest Patents

Among his latest inventions are remarkable bispecific proteins that target BAFF (B-cell activating factor) and B7RP1 (B7-related protein 1). These proteins serve as potential therapeutic agents, providing new avenues for treatment. Furthermore, Hsu has developed bispecific antigen-binding proteins that interact with TL1A and TNF-alpha, which could play a crucial role in managing autoimmune and inflammatory diseases. The innovations also include various formats, such as tetrameric immunoglobulins and IgG-scFv fusions, enhancing their effectiveness in clinical applications.

Career Highlights

Hsu's career encompasses significant roles in leading companies within the biotechnology sector, including Amgen and Tularik. These positions have provided him with invaluable experience in drug development and research, allowing him to translate his inventive ideas into practical medical solutions.

Collaborations

Throughout his career, Hsu has collaborated with notable professionals, including Frederick W Jacobsen and Ian Nevin Foltz. These partnerships have fostered an environment of innovation, leading to breakthroughs in the design and application of bispecific proteins.

Conclusion

Hailing Hsu's contributions to the field of biopharmaceuticals underscore the importance of innovation in medical technology. His extensive patent portfolio not only highlights his inventiveness but also reflects his commitment to advancing therapeutic options for patients. As he continues to develop novel solutions, Hsu's work is poised to make a lasting impact on the industry.